TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07524322: Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Sponsor: Regor Pharmaceuticals Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 63 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,895,584

Rescue Site Savings

+$2,576,112

Unlock Full NCT07524322 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07524322 Rescue Dossier →